Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Acacia Lifesciences Pvt Ltd

    Acacia Life Sciences Pvt Ltd was incorporated in May 2006 by Mr K. Gopi and three other promoters with its Research and Development centre at Hyderabad and Multi-purpose Plant

  • No Image
    Acara Bioherb Pvt Ltd

    Acara Bioherb Pvt Ltd incorporated in the year 2012 is engaged in manufacturing of herbal cosmetic creams and hair colouring serum, fragrances under the brand Acara. Its produ

  • No Image
    Accure Labs Pvt Ltd

    Accure is currently engaged in around 25 countries. They have established presence in South East Asia, Asia Pacific, Africa, North America, EU & EEA, MENA, Latin America and CI

  • No Image
    Actgen Pharma Pvt Ltd

    Actgen Pharma is a subsidiary of Hiran Orgochem Ltd, based in Mumbai . It manufactures API's under CGMP guidelines.